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In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent 
effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, 
but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, 
the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed 
the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endoge-
nous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising 
drugs related to the scope of pharmacogenetics currently under study. 
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INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelop-
mental disorder characterized by impaired social skills, 
communication deficits and repetitive behaviors, interests 
or activities.1) It is frequently associated with comorbid 
disorders such as intellectual disability, obsessive com-
pulsive disorder, epilepsy, Tourette syndrome, attention 
deficit/hyperactivity disorder (ADHD), tuberous sclerosis 
and Fragile X syndrome (FXS).2) The Centers for Disease 
Control and Prevention3) currently estimates the preva-
lence of ASD in the USA at 1 in 88 children (1 in 54 boys 
and 1 in 252 girls). ASD affects more children than are af-
fected by diabetes, acquired immune deficiency syn-
drome (AIDS), cancer, cerebral palsy, cystic fibrosis, 
muscular dystrophy or Down’s syndrome combined.3) 
Although genetic predisposition and environmental con-
tributors have been implicated in the pathophysiology of 
ASD, the precise mechanisms underlying the pathophysi-
ology of this disorder remain unknown and there are no es-
tablished methods of prevention or cure.1)
The Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-5; American Psychiatric 
Association [APA] 2013)4) was published in 2013 and 
combined several previously separate disorders under the 
ASD umbrella. These disorders are pervasive devel-
opmental disorder (PDD) including autistic disorder, 
Asperger’s disorder, childhood disintegrative disorder 
and PDD not otherwise specified (PDD NOS). Rett’s dis-
order was excluded as a genetic disorder. The DSM-5 now 
conceptualizes the separate disorders as a single condition 
with different levels of symptom severity in two core do-
mains; (1) social communication and social interaction, 
(2) restricted repetitive behaviors, interests, and activ-
ities.4) Such changes could influence diagnostic methods 
and therapeutic approaches which would raise both con-
cerning and favoring perspectives.5) The concerned posi-
tion argues that the number of patients taking medication 
could be inflated, since separate disorders are combined 
into a single disorder. Also, since the new category is a 
re-organization based on symptoms, not a categorization 
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Table 1. Drugs and substrates based on etiological pathogenesis of autism spectrum disorder
Etiological classification Drugs and substrates Design, setting and sample
Cholinergics Tacrine 2-week, open-label, 20 mg daily, (n=3)11)
Rivastigmine 12-week, open-label, 0.4 ml twice daily, (n=32)12)
Galantamine 12-week, open-label, 2 mg twice daily, (n=13)14)
Donepezil 6-week, RCT, additional 6-week open-label, 2.5 mg daily, (n=43)17)
10-week, parallel-groups, RCT, 10 mg daily, (n=34)18)
Glutamatergics NMDA antagonists 10-week, RCT, memantine 20 mg daily, (n=40)27)
8-week, open-label, STX209 10 mg twice daily (age 6-11 years) or three times daily (age 
12-17 years), (n=32)28)
4-week, open trial, 20 mg daily, (n=4)29)
8-week, open-label, memantine 0.4 mg/kg daily, (n=14)30)
mGluR antagonists 6-hour, pilot open-label, fenobam 50-150 mg, (n=12)32)
GABA agonists 4-week, crossover, RCT, AFQ056 150 mg twice daily, (n=30)33)
Neuropeptides Secretin 8-week, single-blind cross-over, 8-12 units/kg IV, (n=12)40)
Naltrexone 6-week, parallel-group, 1 mg/kg daily, (n=41)45) 
Oxytocin 4-hour, crossover, RCT, gradually titrated up IV, (n=15)54)
45-minute, crossover, RCT, 18 IU (age 12-15 years) or 24 IU (age 16-19 years) IN, (n=16)55)
1-week, RCT, 24 IU IN, (n=13)56)
4-week, open-label, 8 IU daily, (n=1)57)
CAM Chelating agents 4-hour, open-label, DMSA 10 mg/kg, (n=95)71)
13-months, RCT, succimer 1,050 mg/M2 daily for the first 7 days (700 mg/M2 daily 
thereafter), (n=780)72)
Vitamins 3-month, RCT, multi-vitamin/mineral supplement, different dosage each, three times 
daily, (n=141)74)
Omege-3 6-weeks or 12-weeks, RCT, EPA 0.84 g and DHA 0.7 g IV daily; EPA 0.7 g and DHA 0.46 
g IV daily, (n=37)83)
Promising drugs N-acetylcysteine 12-week, RCT, 900 mg up to 2,700 mg daily, (n=33)91)
Purinergic antagonists 18-week, C57BL/6J mice, suramin 10 or 20 mg/kg IP weekly, (n=168)92)
Rapamycin Tsc2+/- mice, different dosage and route103)
PTEN modulators PTEN haplo-insufficient mice aged 20-29 weeks showed aberrant social behavior like 
autism.109)
RCT, randomized controlled trial (with placebo controlled); CAM, complementary and alternative medicine; NMDA, N-methyl-D-aspartate; 
mGluR, metabotropic glutamate receptor; GABA, γ-aminobutyric acid; succimer, dmercaptosuccinic acid; DMSA, 2, 3-dimercaptosuccinic 
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PTEN, phosphatase and tensin homolog deleted on chromosome 10; IN, 
intranasal; IV, intravenous; IP, intraperitoneal.
based on etiological or biological evidence, conservative 
treatment would still continue.6) However, there could be 
positive effects in matters such as applying and assessing 
therapeutic effects since assessment could be done by a 
single standard. In other words, results from previous 
studies on five separately diagnosed patients or disorders 
may prove difficult to interpret and combine while a single 
diagnostic approach to similar developmental disorders 
simplifies the investigation of etiology and pathogenesis. 
A way to maximize the advantages of such changes as a 
single disorder would be to investigate the etiology and 
pathogenesis by medication.7) Hence, the authors intend 
to contribute to the research for pathogenesis and etio-
logical treatment of ASD by reviewing medicine based on 
pathogenic approach besides current conservative treat-
ments (Table 1).
MAIN SUBJECTS
Cholinergics
Mechanism
Acetylcholine (Ach) acts at two different types of chol-
inergic receptors, namely muscarinic and nicotinic 
receptors. Muscarinic receptors bind Ach as well as other 
agonists and antagonists. Nicotinic receptors are less 
abundant than the muscarinic type in the central nervous 
system. Ach is removed from the synapse through hydrol-
ysis into CoA and choline by the enzyme acetyl choline-
sterase. Ach modulates attention, novelty seeking, and 
memory via the basal forebrain projections to the cortex 
and limbic structures.8) Recent animal studies show the 
amelioration of autism-relevant phenotypes, including 
decreasing cognitive rigidity, improving social prefer-
ence, and enhancing social interaction through the aug-
mentation of Ach in the synaptic cleft by inhibiting 
acetylcholinesterase.9) Interestingly, cholinergic enhance-
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ment is shown to positively modulate selective attention 
and emotional processing, which are impaired in autistic 
individuals.10) 
Clinical implication
Tacrine
Niederhofer11) reported that Tacrine may be modestly 
effective in the short-term treatment of irritability, hyper-
activity, inadequate eye contact, and inappropriate speech 
in children with autistic disorder. Although there was no 
sign of hepatotoxicity in a short-term trial with Tacrine, its 
registration in many countries has been cancelled because 
of late hepatotoxicity. 
Rivastigmine
Chez et al.12) documented statistically significant im-
provements on behavioral measures, expressive vocabu-
lary, and core features of autism in a 12-week, open label 
trial of rivastigmine involving 32 children with ASD.
Galantamine
The use of galantamine (4 mg/day) enhanced ex-
pressive language in an open-label study of three adults 
with autism.13) Nicolson et al.14) reported that 13 children 
with autism experienced significant improvements in irri-
tability, social withdrawal, and inattention with galant-
amine (4 to 24 mg/day) in a 12-week open-label study, as 
rated by parents. Anger and autistic behavior were also re-
duced when clinicians observed. 
Niederhofer et al.15) conducted a placebo controlled, 
double blind crossover randomized controlled trial inves-
tigating the efficacy of galantamine in 20 boys with au-
tistic disorders. Treatment with galantamine was well tol-
erated and led to improvements in irritability, hyper-
activity, eye contact and inappropriate speech compared 
with placebo. 
Donepezil
From a retrospective study of donepezil in 8 children 
with autism, the irritability and hyperactivity subscales 
were decreased, but the inappropriate speech, lethargy, 
and stereotypies subscales did not change.16) In a 6-week 
randomized double blind placebo controlled study of 43 
children with ASD, the use of donepezil (1.25 to 2.5 mg/d) 
led to improvements in expressive and receptive language 
as well as a decrease in overall autistic behavior compared 
with placebo.17) Handen et al.18) reported that short-term 
treatment with donepezil may have limited impact on cog-
nitive functioning in ASD.
Glutamatergic and GABA
Mechanism
Glutamate, the major excitatory neurotransmitter, is 
highly concentrated throughout the brain and is crucial for 
neuronal plasticity and maintenance of cognitive func-
tions.19) However, excess glutamate has been shown to be 
a potent neurotoxin that leads to neuronal cell death19) and 
is deemed to play a role in the pathophysiology of some 
neuropsychiatric disorders, such as schizophrenia, ob-
sessive-compulsive disorder and Alzheimer’s disease.20)
Several mechanisms related to a hyperglutamatergic hy-
pothesis of autism are being proposed. First, Fatemi et 
al.21) reported glutamate increase due to dysfunctions in 
enzymes responsible for converting glutamate to gam-
ma-aminobutyric acid (GABA). Yip et al.22) reported con-
sistent findings regarding increase in glutamate concen-
tration due to fewer Purkinje cells in autistic cerebella and 
related enzymes. Second, there are proposals suggesting 
that glutamate transporters (excitatory amino acid trans-
porters), which translocate glutamate from endothelial 
cells to the extracellular fluids, are involved in autism’s 
pathophysiology.23) Third, Brown et al.24) and Ortinski et 
al.25) reported that decreased glutamine and increased glu-
tamate due to dysfunctions in the glutamate-glutamine cy-
cle is significantly involved in ASD development.
Clinical implication
N-Methyl-D-aspartate (NMDA) antagonists
Blocking glutamatergic transmission with MK-801 or 
memantine treatment, and to a lesser extent with 2-meth-
yl-6-(phenylethynyl) pyridine treatment, reversed the im-
paired social behaviors and seizure susceptibility of pre-
natally valproate-exposed rat offspring used as an animal 
model of ASD.26)
From four open label human studies investigating the 
use of memantine for PDD,27-30) subjects taking mem-
antine demonstrated symptomatic improvement, in par-
ticular behavioral. Nevertheless, the lack of double-blind 
design or control groups is considered a weakness of these 
studies.31)
Metabotropic glutamate receptor (mGluR) antagonists
The first mGluR antagonist to go into human trials was 
fenobam, which was studied in 12 patients with FXS in a 
pilot open-label study.32) About half of the patients 
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showed improved eye contact and 25% showed improve-
ments in social interaction with a single dose of the drug. 
The next mGluR antagonist to reach human trials was 
AFQ056. This agent was studied in a double-blind place-
bo-controlled crossover study of 30 patients with FXS.33) 
Following 4 weeks of treatment, there was no significant 
improvement found when the entire sample was analyzed 
as a single group. However, post hoc analysis revealed 
that the seven patients with fully methylated mutations 
showed significant improvements in the Aberrant Behav-
ior Checklist (ABC), Clinical Global Impression Scale 
(CGI) and the Social Responsiveness Scale as well as spe-
cific improvements in subscales measuring stereotypic 
behavior, hyperactivity, inappropriate speech and re-
stricted interests. This effect was not observed in patients 
with partial methylation at the Fragile X Mental 
Retardation-1 (FMR1) promoter (the majority of patients 
in the original cohort).
γ-Aminobutyric acid (GABA) agonists
STX209, a GABA agonist, was administered to 63 pa-
tients with FXS in a double-blind placebo-controlled 
crossover phase II study.34) Following four weeks of treat-
ment, results indicated an improvement in the parents’ rat-
ings for the three most problematic behaviors for their 
child as well as in the ABC Avoidance Scale (ABC-AS). 
However, there was no significant effect on other vali-
dated FXS factor scores on the ABC. When a subgroup of 
more severely affected patients was analyzed separately, 
in addition to the above effects, significant improvements 
were observed on the Vineland-Socialization measure of 
adaptive functioning and on the CGI Scale. Anecdotal re-
ports also indicated that the patients were more communi-
cative when on STX209 compared to the placebo. 
Erickson et al.35) reported that improvements were ob-
served on several outcome measures including the ABC- 
Irritability (the primary endpoint) and the Lethargy/Social 
Withdrawal subscales, the Social Responsiveness Scale, 
the Children’s Yale-Brown Obsessive Compulsive Scale 
Pervasive Developmental Disorder (CY-BOCS-PDD), 
and clinical global impression scales. 
Neuropeptides
Unlike cholinergics or glutamatergics, neuropeptide 
medication and substances are based on different mecha-
nisms and thus are described separately.
Secretin
Mechanism
The 27 amino-acid polypeptide secretin is a gastro-
intestinal polypeptide usually used to treat peptic ulcers 
and evaluate pancreatic function.36) Some animal study re-
sults have also suggested that secretin affects the central 
nervous system and may function as a neurotransmi-
tter.37,38)
Interest in secretin for the treatment of ASD stemmed 
from a non-blinded, uncontrolled case series of three chil-
dren with ASD who received synthetic intravenous secre-
tin during a routine endoscopy evaluation for gastro-
intestinal problems.39) The report noted social, cognitive, 
and communicative gains after the first infusion and after 
a second infusion given weeks later. Following this report, 
the use of secretin became widespread.
Clinical implication
Children with autism have symptoms consistent with a 
central 6R-5, 6, 7, 8-tetrahydro-L-biopterin (BH4) defi-
ciency.40) BH4 deficiency can result in low production of 
monoamine neurotransmitters, including serotonin, dop-
amine, and norepinephrine. There is a significant amount 
of evidence that deficits in these monoamine neuro-
transmitters are present in some children with autism. 
Research results suggest that secretin ameliorates core 
symptoms of ASD through the activation of metabolic 
turnover of dopamine in the central nervous system via 
BH4.40) Recently, thorough review of 16 randomized trials 
with a placebo control group involving over 900 children 
with ASD was conducted. Williams et al.41) concluded 
that there was no evidence that either a single or multiple 
dose of intravenous secretin improved the main problems 
seen in ASD. Currently it should not be recommended or 
administered as a treatment for ASD.41)
Nonetheless, it may be worthwhile to review the results 
of Toda et al.40) which suggest that secretin can be effec-
tive for ASD patients who have increased BH4 levels. 
Toda et al.40) evaluated the clinical effects of intra-
venously administered secretin in 12 children with autism. 
The homovanillic acid and BH4 levels in cerebrospinal 
fluid were increased in all children with improvements in 
the Autism Diagnostic Interview-Revised (ADI-R) score. 
In contrast, patients without elevated BH4 levels showed 
no improvement in the score. These findings suggest that 
secretin activates metabolic turnover of dopamine in the 
central nervous system via BH4, subsequently improving 
symptoms.40) Consequently, the role of secretin and its 
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mechanism of action in the central nervous system should 
be investigated for possible applications with patients 
who have changes in brain metabolism. 
Naltrexone
Mechanism
Naltrexone is an opioid receptor antagonist that is com-
monly used for the treatment of alcoholism and opioid 
dependence.42) It has also been used to treat children with 
autism based on the hypothesis that autism is related to hy-
persecretion of brain opioids, reflecting dysfunction in the 
pineal-hypothalamic-adrenal axis.43) Several studies have 
reported that naltrexone decreases challenging aspects of 
autism such as self-injurious behavior (SIB),44) and 
hyperactivity.45) One of the theories put forth to explain 
the symptoms of ASD involves the dysfunction of the en-
dogenous opioid system which is involved in hedonic 
processing of reward, positive reinforcement, impulsivity, 
and potentially craving in alcohol dependence. The brain 
opioid hypothesis of social attachment posits that reduc-
tions in opioid activity should increase the desire for social 
companionship, while increases in this system should re-
duce the need for affiliation.46)
Clinical implication
Campbell et al.45) randomly assigned 41 hospitalized 
young children (ages 2.9-7.8 years) with autism to either 
three weeks of naltrexone (1 mg/kg/day) or placebo 
treatment. Patients treated with naltrexone showed sig-
nificant improvement in hyperactivity, but no improve-
ment in learning or core autistic symptoms. Symons et 
al.44) reviewed published literature from 1983 to 2003 
documenting the use of naltrexone for the treatment of 
SIB. A sample of 27 research articles involving 86 sub-
jects was reviewed. Eighty percent of the subjects showed 
improvements during naltrexone administration and 47% 
of the subjects exhibited reductions in SIB by as much as 
50% or greater. In studies reporting dose levels in milli-
grams, males were more likely than females to respond.44) 
No significant relations were found between treatment 
outcomes and autism status or form of self-injury. 
Subsequently, naltrexone may be an option worthy of con-
sideration in treatment-refractory SIB, but the over-
arching conclusion from the mixed literature on this drug 
is that there is a pressing need for studies that will help to 
identify potential responders from within the heteroge-
neous population of persons with intellectual disability 
who self-injure.47)
Oxytocin
Mechanism
Oxytocin (OT), a neuropeptide that is secreted from the 
posterior pituitary, plays an important role in social affili-
ation and attachment.48) It is also a promising candidate for 
treatment of social impairments in ASD patients. OT is 
mainly synthesized in magnocellular neurons of the su-
praoptic and paraventricular nuclei of the hypothalamus 
that project to the posterior pituitary. From the pituitary, it 
is released into the bloodstream to act as a hormone. In ad-
dition, neurons in the paraventricular nuclei project to var-
ious limbic, mid- and hindbrain structures containing OT 
receptors. Within the brain, OT can act both as a neuro-
transmitter and as a neuromodulator.49)
The OT receptor gene (OXTR) is located on chromo-
some 3p25, spans 17 kb,50) and encodes a 389 amino acid 
polypeptide with seven transmembrane domains belong-
ing to the class I G-protein-coupled receptor family.51) 
Genetic variations influencing the number, organization, 
or functioning of OT receptors would be expected to influ-
ence the efficacy of the OT signal in the brain. Indeed, ini-
tial studies have linked variations in OXTR to suscepti-
bility for mental disorders characterized by social deficits, 
such as ASD.52,53)
Clinical implication
OT has been implicated in states of aberrant social 
function. Previous attempts to improve social deficits in 
young ASD patients via OT nasal spray revealed positive 
results, specifically, improved retention of affective 
speech comprehension,54) enhanced mind-reading per-
formance,55) more frequent engagement in positive social 
interactions, and enhanced feelings of trust and preference 
towards partners within positive interactions.56)
There is a case report of a 16-year-old girl with ASD 
whose social impairments and secondary disabilities were 
improved by long-term (2 month) nasal oxytocin admin-
istration without any adverse effects.57) Social interaction, 
communication, and aggressive behavior were all im-
proved. Her ABC scores decreased from 69 to 7. This case 
suggests that long-term oxytocin administration is a safe 
treatment for improving social impairments even in fe-
male patients with ASD. 
At a biochemical level, it is still unclear whether periph-
eral OT levels are correlated with OT levels in the brain,58) 
and whether and how intranasally administered OT reach-
es the receptors in the brain.59) If the pathway responsible 
for the behavioral effects of OT treatment is initially pe-
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ripheral followed by increased central OT levels rather 
than initially central, then nasal administration is a sub-
optimal method for increasing central OT levels.60) 
Despite not knowing the mechanism for how OT pene-
trates the limbic system and reaches its receptors, in-
dividuals diagnosed with autism or related disorders seem 
to profit most from application of OT, and their so-
cial-communicative skills might improve significantly, 
based on the results of the trials.48) 
Complementary and Alternative Medicine (CAM)
Although numerous CAM lacks scientific evidence, it 
is broadly used due to its recognition as a treatment with 
lesser side effects than general medicine.61) The percent-
age of children with ASD in the USA who are reported to 
receive CAM is about 2-50%62) and in some studies, it is 
estimated to be up to 50-70%.61) Levy and Hyman61) clas-
sified CAMs according to the strength of the evidence: 
grade A with randomized controlled trials, reviews and/or 
meta-analyses; grade B with other evidence such as iso-
lated well-designed controlled and uncontrolled studies; 
grade C with case reports or theories. For example, vita-
min C and omega-3 fatty acids are placed as grade B and 
chelation as grade C. Previous studies on CAM up to the 
current date need to be investigated63) and we reviewed 
commonly used substances.
Chelating agents
Mechanism 
Some articles emphasized that rising levels of autism 
could be related to environmental exposure to toxins.64,65) 
DeSoto and Hitlan66) reviewed published research studies 
examining the relationship between toxic metal exposures 
and the risk of a subject being diagnosed with an ASD: 
74% (43 of 58) of the studies showed a significant rela-
tionship between an ASD and toxic metal exposure. Hair 
analysis showed that autistic children have elevated hair 
concentrations for aluminum, arsenic, cadmium, mercury, 
antimony, nickel, lead, and vanadium.67) Also, there was a 
significant positive correlation between lead and verbal 
communication (p=0.020) as well as general impression 
(p=0.008). These data support the theory that heavy met-
als play a role in the development of ASD. Among the 
heavy metals, mercury and lead especially have been the 
main focus of research on the causes of ASD symptoms. 
Low level of mercury has clearly been demonstrated to 
cause specific damage to developing human brain cells.68) 
Even very low level of lead exposure in childhood may 
cause lifelong impairment of attention, memory and 
learning.69)
Clinical implication
It is estimated that ASD children have impaired methyl-
ation, sulfation and anti-oxidant processes associated with 
the detoxification process of heavy metals.70) Urine tests 
are better conducted by the using chelating agent, ethylene 
diamine tetraacetic acid (EDTA) or 2, 3-dimercapto-
succinic acid (DMSA) to measure heavy metal concen-
trations in the body.71) 
The oral chelater, meso-2, 3-DMSA is the most com-
monly used chelating agent. It binds with heavy metals of 
the opposite charge and results in an increase in urinary 
excretion of heavy metals from the body.66) However, it 
does not improve cognition, behavior, or neuropsycholo-
gical function.72) Despite the limitations of the studies, the 
cumulative findings suggest that chelation might be a via-
ble form of treatment in some individuals with an ASD 
who have elevated heavy metal content or biochemical 
changes.73)
Vitamins 
Mechanism
Vitamins are essential for human health due to their crit-
ical function as enzymatic cofactors for numerous re-
actions in the body.74) Oral vitamin supplementation is 
beneficial in improving the nutritional and metabolic sta-
tus of children with ASDs. These include improvements 
in methylation, glutathione, oxidative stress, sulfation, ad-
enosine triphosphate (ATP), nicotinamide adenine dinu-
cleotide phosphate (NADPH), and oxidized form NADPH 
(NADP+).74) A pilot study suggests that plasma concen-
trations of the exogenous antioxidants, vitamins E and A, 
as well as lycopene in autistic subjects were at insufficient 
levels.75) The environment influences responsive genes 
and, subsequently the genome. Vitamin D is a neuro-
steroid76) and follows this type of genetic organization.77) 
Cui et al.78) have determined that vitamin D is important 
for neural development and its deficiency negatively al-
ters brain structure and function.
Clinical implication
A randomized, double blind, placebo-controlled study 
on the effects of supplements on ASD was conducted for 
three months. One group received multivitamin and min-
eral supplements, while the other group received place-
bos.74) The supplement group showed significantly great-
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er improvements than the placebo group on the Parental 
Global Impressions-Revised (PGI-R). The most sig-
nificant improvements on the PGI-R subscales were in the 
areas of hyperactivity, tantrumming, overall, and re-
ceptive language. 
Vitamin D has also been actively studied. A Japanese 
case report showed that ASD children improved in symp-
toms during the summer.79) Vitamin D is highly seasonal 
with a summertime surfeit and a wintertime deficit. It also 
has remarkable antioxidant, anti-inflammatory, and an-
ti-autoimmune properties. Animal experiments provide 
data for vitamin D’s role in brain proliferation, differ-
entiation, neurotrophism, neuroprotection, neurotrans-
mission, and neuroplasticity.80) It can be assumed that vi-
tamin D may have an effect on improving ASD sym-
ptoms.
According to a survey of 539 physicians, vitamin/min-
eral supplements are the most widely recommended medi-
cal interventions for autism, and are recommended by 
49% of physicians for children with autism.81) Vitamin 
supplement is well-tolerated, with few side effects, there-
fore it can be a candidate for adjuvant therapy for ASDs. 
However, more studies on the effectiveness of vitamins 
for ASD treatment are necessary. 
Omega-3
Mechanism
Essential fatty acids are polyunsaturated fatty acids 
which are not produced by the human body but are neces-
sary for normal development and functioning of the brain 
and immune system.82) There are several key types of es-
sential fatty acids. Fish and seafood are major sources of ei-
cosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), which are long chain omega-3 fatty acids.83) It has 
been suggested that difficulties associated with ASD may 
be explained in part by lack of omega-3 fatty acids, and that 
supplementation of these essential fatty acids may lead to 
an improvement of symptoms.83) Omega-3 deficits or im-
balances have been linked to various neurodevelopmental 
disorders, such as ADHD, dyslexia, and dyspraxia.84)
Clinical implication
From the meta-analysis on the efficacy of omega-3 fatty 
acids for three primary outcomes (social interaction, com-
munication, and stereotypy) and one secondary outcome 
(hyperactivity), 37 children diagnosed with ASD who 
were randomized into groups that received either omega-3 
fatty acids supplementation or a placebo were included.83) 
From this meta-analysis, there was no evidence that ome-
ga-3 supplements had an effect on social interaction, com-
munication, stereotypy, or hyperactivity. To date there is 
no evidence-based proof that omega-3 fatty acids supple-
mentation is effective as a treatment for autism.85)
Promising Drugs
New therapeutic methods including at the gene and 
chromosome levels, are currently being studied to regu-
late ASD core symptoms. We intend to review the com-
monly used agents. 
N-Acetylcysteine
Mechanism
N-Acetylcysteine (NAC) targets a diverse array of fac-
tors germane to the pathophysiology of multiple neuro-
psychiatric disorders including glutamatergic transmi-
ssion, the antioxidant glutathione, neurotrophins, apopto-
sis, mitochondrial function, and inflammatory path-
ways.86) NAC is the N-acetyl derivative of the amino acid 
L-cysteine and is rapidly absorbed following oral admini-
stration.87) L-Cysteine is rapidly oxidized to cystine in the 
pro-oxidant milieu of the brain. Cystine is the substrate of 
the cystine−glutamate antiporter, which shuttles gluta-
mate out of the cell in exchange for cystine, thereby regu-
lating extracellular glutamate levels and facilitating cys-
teine entry into the cell.88) Inside the cell, cystine can be re-
duced to cysteine, which is the rate-limiting component of 
the key endogenous antioxidant molecule glutathione 
(GSH).89) The ability of NAC to regulate both cysteine and
−glutamate antiporter activities as well as the biosyn-
thesis of GSH is the key to its therapeutic efficacy. In au-
tism, dysregulation of redox biology, inflammation, and 
glutamate transmission have been noted.90)
Clinical implication
From recent tantalising data on the efficacy of NAC in 
autism, participants were administered 900 mg daily for 4 
weeks then gradually increased to 2,700 mg daily over a 
period of 8 weeks.91) In this 12-week, double-blind, 
randomized, placebo-controlled study of NAC, signifi-
cant improvements on the ABC irritability subscale in the 
NAC group were reported. Improvements were also ob-
served on the Repetitive Behavior Scale-Revised stereo-
typies measure and mannerisms scores of Social Respon-
siveness Scale. 
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Purinergic antagonists
Mechanism
Mitochondria act to connect genes and environments 
by regulating gene-encoded metabolic networks accord-
ing to changes in the chemistry of the cell and its 
environment.92) Mitochondrial ATP, adenosine diphos-
phate (ADP), uridine triphosphate (UTP), and uridine di-
phosphate (UDP) are mitokines. Mitokines are molecules 
produced by mitochondria that act as signaling molecules 
when outside the cell, and have separate metabolic func-
tions inside the cell. Outside the cell, they bind to and reg-
ulate purinergic receptors present on the surface of every 
cell in the body.92) ATP has been found to be a co-neuro-
transmitter at every type of synaptic junction studied to 
date.93) Excess extracellular ATP (eATP) is an activator of 
innate and adaptive immunity,94) a danger signal and a 
damage-associated molecular pattern (DAMP) that is che-
motactic for neutrophils.95) It is also a potent regulator of 
microglial activation, death, and survival.96)
Clinical implication
Naviaux et al.92) used the maternal immune activation 
mouse model of gestational poly (IC) exposure and treat-
ment with the non-selective purinergic antagonist suramin 
to test the role of purinergic signaling in C57BL/6J mice. 
They found that antipurinergic therapy corrected 16 multi-
system abnormalities that defined the ASD-like pheno-
type in this model. These included correction of the core 
social deficits and sensorimotor coordination abnormal-
ities, prevention of cerebellar Purkinje cell loss, correc-
tion of the ultrastructural synaptic dysmorphology, and 
correction of the hypothermia, metabolic, mitochondrial, 
P2Y2 and P2X7 purinergic receptor expression, in addi-
tion to ERK1/2 and CAMKII signal transduction 
abnormalities. However, suramin as a treatment for pros-
tate cancer causes numerous reversible complications 
such as severe urticarial reaction, adrenal damage, and im-
paired renal function. Neurotoxicity has been the most 
significant complication.97)
Rapamycin
Mechanism
Rapamycin is an immunosuppressant originally identi-
fied as an antifungal agent in isolates from Streptomyces 
hygroscopicus.98) Rapamycin strongly binds to the 
FK506- binding protein (FKBP), and the complex sub-
sequently binds and inhibits mTOR, a serine/threonine 
kinase implicated in transcription, cytoskeleton dynam-
ics, ubiquitin-dependent protein degradation, autophagy, 
and membrane trafficking.99) In the nervous system, 
mTOR regulates axon guidance, dendrite arborization, 
synaptogenesis, and synaptic plasticity.100) Importantly, 
rapamycin treatment alleviates several pathogenic traits 
observed in in vivo and in vitro models of Alzheimer’s dis-
ease, Parkinson’s disease, and polyglutamine diseases.101)
Clinical implication
Tuberous sclerosis complex (TSC) is a genetic disorder 
with high rates of comorbid ASD that result from muta-
tions of either TSC1 or TSC2.102)
Ehninger et al.103) reported that a brief treatment with 
the mTOR inhibitor, rapamycin, in Tsc2+/- adult mice res-
cues not only the synaptic plasticity, but also the behav-
ioral deficits in the animal model of tuberous sclerosis. 
The social dysfunction and behavioral inflexibility of pur-
kinje cell-specific Tsc1 mutant mice were also improved 
by rapamycin.104)
Phosphatase and tensin homolog deleted on 
chromosome 10
Mechanism
Phosphatase and tensin homolog deletion on chromo-
some 10 (PTEN) plays a pivotal role in controlling intra-
cellular signaling for cell survival and proliferation by in-
hibiting the PI3K/Akt pathway. PTEN dysfunction is as-
sociated with several neoplastic diseases.105) Unlike sev-
eral cellular proteins which are activated by phosphor-
ylation, PTEN is inactivated upon phosphorylation by 
specific kinases that phosphorylate serine and threonine 
residues in its C-terminal region. Therefore, development 
of therapeutic agents that specifically target kinases and 
kinase-domain-containing proteins affecting PTEN would 
lead to the treatment of PTEN-related diseases.
Three genetic mutations in the PTEN gene (H93R in 
exon 4 and D252G and F241S in exon 7) have been identi-
fied which play a role in macrocephaly/autism synd-
rome.106) Targeted inactivation of PTEN in the differen-
tiated neurons of the cerebral cortex in mice resulted in in-
creased response to sensory stimuli with neuronal hyper-
trophy, including hypertrophic and ectopic dendrites and 
axon tracts with increased synapses. This suggests that de-
fects in PTEN cause macrocephaly and autistic syndrome 
in mice.107)
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Clinical implication
Novel drug candidates to modulate PTEN are currently 
used for cancer treatment such as primary intraocular lym-
phoma, breast cancer, lung cancer, prostate cancer, T-cell 
Leukemia, B-non-Hodgkin’s lymphoma and metastatic 
colorectal cancer.105) In addition, 2-dimethyl-amino- 
4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, CK2 in-
hibitor) and CT99021 regulate leptin and are used for dia-
betes and obesity treatment.108) PTEN is known to have an 
important role in cardiovascular diseases, Alzheimer’s 
disease, ASD and Parkinson’s disease.105) Napoli et al.109) 
suggest a pathogenic mechanism of the PTEN-p53 axis in 
mice with aberrant social behavior. However, there is no 
evidence for treating psychiatric diseases including ASD 
with PTEN modulators and, therefore, further study is 
needed.
CONCLUSION
Pharmacotherapy in patients with ASD is focused on 
immediate problems in everyday life such as, anxiety, 
seizures, hyperactivity, aggressive behavior, self-harm 
and stereotypy. ASD, however, is a chronic and lifelong 
condition beginning in early childhood. Etiological phar-
macotherapy, in addition to conservative treatment, is 
necessary. In the current article, we introduced pharmaco-
logical treatments based on currently ongoing ASD etio-
logical pathogenic studies. 
Although some medications based on neurotransmitter 
hypothesis such as cholinergic and glutamatergic reveals 
as effective drug and some of the treatments stands out 
mostly as an adjuvant therapy, some have no relation 
whatsoever regarding effects and pathogenesis. Research 
on the gene and synapse level medication was also 
introduced. 
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